BuzzHere’s a polished English translation of the Chinese title: **”2026 Disney Animation Film Carnival” Grandly Opens** Alternatively, for a more natural and engaging tone: **”2026 Disney Animation Film Carnival” Kicks Off in Spectacular Style**rocky TTJune 26, 2026
Buzz**[ASCO 2026 Live] Ascentage Pharma Releases Data on Olverembatinib (耐立克®) for CML-LBP and Ph+ BCP-ALL, Poised to Fill Treatment Gap in Blast Phase**rocky TTJune 26, 2026
BuzzHere’s a polished English translation of the Chinese title: **Long-Term Follow-Up Results of CARsgen’s舒瑞基奥仑赛 Injection for First-Line Sequential Treatment of Gastric Cancer Presented at the 2026 ASCO Annual Meeting** Alternatively, if you’d like a more concise and natural-sounding version: **Long-Term Follow-Up Results of CARsgen’s CT041 (舒瑞基奥仑赛) for First-Line Sequential Therapy in Gastric Cancer Unveiled at 2026 ASCO** Note: “舒瑞基奥仑赛” is likely the Chinese brand name for CT041 (a CAR-T therapy targeting Claudin18.2). If you prefer to keep the original name in the translation, you can use “舒瑞基奥仑赛 Injection” or simply “舒瑞基奥仑赛” with a brief explanation.rocky TTJune 26, 2026
BuzzHere’s a polished English translation of the Chinese title: **”With Love as the Promise, Cigna-CMB Leverages Its ‘Insurance + Health’ Expertise to Safeguard a Colorful Childhood”** Alternatively, a more concise version: **”A Promise of Love: Cigna-CMB Protects Vibrant Childhoods with ‘Insurance + Health’ Expertise”**rocky TTJune 26, 2026
BuzzHere’s a polished English translation of the Chinese title: **2026 ASCO | Innovent Biologics’ IBI363 (TAK-928) (PD-1/IL-2α-bias) PoC Study Long-Term Follow-Up Results Demonstrate Durable Survival Benefit in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer**rocky TTJune 26, 2026
Buzz2026 ASCO | Innovent Biologics Presents Preliminary PoC Clinical Data on IBI363 (TAK-928), a PD-1/IL-2α-bias Bispecific Fusion Protein, as First-Line Treatment for Advanced Non-Small Cell Lung Cancerrocky TTJune 26, 2026
BuzzHere is a polished English translation of the Chinese title: **D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Demonstrates Landmark Efficacy in Treatment-Naïve NSCLC**rocky TTJune 26, 2026
BuzzFrieslandCampina Launches 2026 Maternal and Infant Immunity Enhancement Initiativerocky TTJune 26, 2026
BuzzAnta Advances Global Running Strategy, Invited to Visit Runner’s World Headquarters, Opening a New Window for International Professional Exchangerocky TTJune 26, 2026
BuzzHere’s a polished English translation of the Chinese title: **”Airbnb Releases 2026 Summer Outbound Travel Trends Report”**rocky TTJune 26, 2026